Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
Tarek Hassanein, Craig J. McClain, Vatsalya Vatsalya, et al.
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 1, pp. 107-115
Open Access | Times Cited: 24

Showing 24 citing articles:

Alcohol-associated liver disease
Bryan Mackowiak, Yaojie Fu, Luca Maccioni, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 3
Open Access | Times Cited: 108
Larsucosterol for the Treatment of Alcohol-Associated Hepatitis
Mitchell Shiffman, Ben L. Da, Aparna Goel, et al.
NEJM Evidence (2025) Vol. 4, Iss. 2
Closed Access
Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Padmanaban Sathiyamoorthy, Jiwon Baek, Sai Sahithya Chamarthy, et al.
Liver Research (2025)
Open Access
Current and future treatment for alcoholic‐related liver diseases
Eileen L. Yoon, Won Kim
Journal of Gastroenterology and Hepatology (2023) Vol. 38, Iss. 8, pp. 1218-1226
Open Access | Times Cited: 11
Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases
Yaping Wang, Jenna Ren, Shunlin Ren
AJP Endocrinology and Metabolism (2024) Vol. 326, Iss. 5, pp. E577-E587
Open Access | Times Cited: 4
Inflammatory liver diseases and susceptibility to sepsis
Hong Lü
Clinical Science (2024) Vol. 138, Iss. 7, pp. 435-487
Closed Access | Times Cited: 4
Management of alcoholic hepatitis: A clinical perspective
Philipp Kasper, Sonja Lang, Hans‐Michael Steffen, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2078-2095
Open Access | Times Cited: 10
Alcohol-associated liver disease: Emerging therapeutic strategies
Benjamin H. Mullish, Mark Thursz
Hepatology (2024) Vol. 80, Iss. 6, pp. 1372-1389
Closed Access | Times Cited: 3
Current epidemiology of chronic liver disease
Richie Manikat, Aijaz Ahmed, Donghee Kim
Gastroenterology report (2023) Vol. 12
Open Access | Times Cited: 8
Alcohol-associated liver disease and public health policies
Shreya Sengupta, Victoria Gill, Jessica L. Mellinger
Hepatology (2024) Vol. 80, Iss. 6, pp. 1323-1341
Closed Access | Times Cited: 2
MetALD: clinical aspects, pathophysiology and treatment
Jordi Gratacós‐Ginès, Sílvia Ariño, Pau Sancho‐Bru, et al.
JHEP Reports (2024) Vol. 7, Iss. 2, pp. 101250-101250
Closed Access | Times Cited: 1
SREBPs as the potential target for solving the polypharmacy dilemma
Xue Wang, Yanqiu Chen, Heyu Meng, et al.
Frontiers in Physiology (2024) Vol. 14
Open Access | Times Cited: 1
New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
Jinming Zhang, Yixin Li, Yang Liu, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Research Priorities and Future Landscape of Clinical Trials in Alcohol-Associated Liver Disease
Anand V. Kulkarni, Ashwani K. Singal, Patrick S. Kamath
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 831-851
Closed Access | Times Cited: 1
Past, Present, and Future Therapies for Alcohol-associated Hepatitis
Sally Condon, Loretta Jophlin
Clinical Therapeutics (2023) Vol. 45, Iss. 12, pp. 1171-1176
Open Access | Times Cited: 3
An overview of recent treatment options for primary sclerosing cholangitis
Ioanna Mousavere
Annals of Gastroenterology (2023)
Open Access | Times Cited: 2
Advances in the management of alcohol-associated liver disease
Ahmad Anouti, Thomas Kerr, Mack C. Mitchell, et al.
Gastroenterology report (2023) Vol. 12
Open Access | Times Cited: 2
Modern Therapeutic Approaches to the Treatment of Alcoholic Hepatitis
A.A. Usanova, Fadi Kuzma, Elvira K. Novikova, et al.
Актуальные проблемы медицины (2024) Vol. 47, Iss. 2, pp. 158-170
Open Access
Severe Alcoholic Hepatitis-optimizing Medical Management: Whether we need a Liver Transplant
Harshal Rajekar
Annals of Clinical Gastroenterology and Hepatology (2024) Vol. 8, Iss. 1, pp. 006-016
Closed Access
Severe alcoholic hepatitis: current concepts and treatment perspectives
О. П. Дуданова
Meditsinskaya sestra (2024) Vol. 26, Iss. 4, pp. 10-13
Closed Access
Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis
Timothy R. Morgan
Clinics in Liver Disease (2024) Vol. 28, Iss. 4, pp. 747-760
Closed Access
The pharmacological management of alcohol-related cirrhosis: what’s new?
Nipun Verma, Ashwin P. Vinod, Ashwani K. Singal
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 14, pp. 1923-1941
Closed Access
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Mustafa Al‐Karaghouli, Meritxell Ventura‐Cots, Yu Jun Wong, et al.
Hepatology Communications (2024) Vol. 8, Iss. 8
Open Access
Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models
Hong Xiao, Shuo Huang, He Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Discovery of 22(S)-23-Phenyl-24-norchol-5-en-3β,22-diol (PFM046) as the First-in-Class, Steroidal, Non-Sulfated Liver X Receptor Antagonist with Anticancer Activity
Lorenzo Pontini, Tommaso Angelini, Pietro Palazzoli, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117136-117136
Open Access
Page 1

Scroll to top